N/A N=17 Effects of Calcium and Phytate on Zinc Absorption
Dietary Zinc Absorption
Primary: Zinc Absorption — 32.8; 26.9; 39.4; 26.2 Percentage of Zinc-65 absorbed — p=0.17
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Zinc and Copper Absorption in Neonates With Bilious Losses
Ileostomy
Primary: Zinc Absorption — 10.9 fractional zinc absorption (%)
Phase 4 N=1,000 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
Anemia · Diarrhea · Iron
Primary: Incidence of Diarrhea — 201; 204; 260; 224 episodes
Phase 3 N=199 Weekly Zinc Chelate Supplementation on Children's Growth
Short Stature
Primary: Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period. — 0.04; -0.08; 0.10; 0.02 Z-Score — p=<0.05
N/A N=16 Iron Bioavailability From MyPyramid Menus
Nonheme Iron Absorption
Primary: Nonheme Iron Absorption — 2.31 percentage of nonheme Iron absorbed
Phase 1 N=48 The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart Failure · Cardiomyopathies
Primary: Change From Baseline in Markers of Cardiac Collagen Turnover (PINP) in Patients With Systolic Heart Failure and Compared With Healthy Controls. — 48.1; 48.1; 39 ng/ml…
N/A N=71 Oral Zinc for the Treatment of Acute Diarrhea in US Children
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88
N/A N=52 Zinc Supplementation and Cardiovascular Risk in HIV
HIV · Inflammation
Primary: Percentage of Participants With Decreased Inflammation Markers sCD14, sTNF-RI, and High Sensitivity C Reactive Protein (Hs-CRP) — 15; 15; 14; 15 Participants
Phase 3 N=143 Micronutrient Sprinkles in a Daycare Center
Diarrhea · Respiratory Infection
Primary: Proportion of Children of Diarrhea Episodes — 19.1; 14.7 percentage of participants
Phase 4 N=12 The Effect of Protein on Calcium Absorption and Gastric Acid Production
Osteoporosis
Primary: Percent Change in Intestinal Calcium Absorption — 34.2; 31.5 percentage of calcium absorption
N/A N=40 Zinc & Bone Health in Thalassemia: The Think Zinc Study
Thalassemia
Primary: Change in Lumbar Spine Bone Mineral Density (BMD) by DXA (Baseline to 18 Months) — 5.9; 1.5 Percent Change — p=0.13
N/A N=25 Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk
Growth and Development
Primary: Fractional Iron Absorption — 2.08; 1.25 % Iron Absorbed — p=0.0944
Early Phase 1 N=95 Zinc Effect on Inflammation and Cardiovascular Risk in HIV
Inflammation · Cardiovascular Diseases · Zinc Deficiency
Primary: Effect of Zinc Supplementation on Zinc Levels at 24 Weeks in HIV-infected Subjects — 8.60; 33.50 absolute change (μg/dL) — p=<0.01
Phase 2 N=25 Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children
Critical Illness
Primary: Plasma Zinc Concentration Over Time — 51.2; 36.4; 37.7; 43.4 mcg/dL
N/A N=95 Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics
Alcoholism
Primary: Primary Endpoint — 13518; 15892; 10849; 15530 Phagocytic Index (PI)
Phase 4 N=23 Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
Acne Vulgaris
Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
N/A N=480 Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio
Phase 4 N=20 Absorption Comparison on Equivalency Value of Genepro Gen2
Analysis, Event History · Absorption; Disorder, Protein
Primary: Weekly Blood Draws to Measure Blood Protein Levels — 7.23; 6.86; 7.43; 7.21 grams per deciliter
Phase 4 N=20 Iron Bioavailability of Fortified Oat Drink
Iron Absorption
Primary: Percent Iron Absorption — 7.14; 5.65 percentage of Iron absorbed
Phase 4 N=26 Effects of Ezetimibe on the Absorption of Oxidized Cholesterol
Hypercholesterolemia
Primary: Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus — 1.925; 2.177 Log(mg*hr/dl) — p=0.03
Phase 2 N=116 Zinc to Treat Tinnitus in the Elderly
Tinnitus
Primary: Change From Baseline in Tinnitus Reaction on the Tinnitus Handicap Questionnaire Scores (0-100) at 4 Months — 22.03; 24.9; 23.7; 25.4 units on a scale — p=>0.05
N/A N=22 A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Secondary Hyperoxaluria · Nephrolithiasis · Hyperoxaluria
Primary: Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period — 2.84 percentage of oxalate absorption
Phase 4 N=620 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
Immunity to Oral Rotavirus Vaccine · Immunity to Oral Polio Vaccine · Shedding of Oral Rotavirus Vaccine
Primary: Number/Percentage of Subjects With Immune Response to Rotavirus Vaccine — 54; 40; 42; 37 Participants
N/A N=2,370 Folic Acid and Zinc Supplementation Trial (FAZST)
Pregnancy · Live Birth · Spontaneous Abortion
Primary: Live Birth — 404; 416; 97; 91 Participants
N/A N=15 Dietary Impact on Intestinal Sulfate Metabolism
Healthy Nutrition
Primary: Effect of Short-term (1-week) Plant- and Animal-based Eating Patterns on Hydrogen Sulfide Production — 69; 103 ppm hydrogen sulfide gas
N/A N=223 Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India
Iron Deficiency · Zinc Deficiency
Primary: Hemoglobin (g/dL) — 10.90; 10.30 g/dL
N/A N=56 Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Anemia
Primary: The Hemoglobin of the Subjects at Baseline and 6 Weeks — 0.38; 0.29; 0.57 g/dl
Phase 2 N=75 Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects
Iron-deficiency
Primary: Change in Hemoglobin Concentration From Baseline to 90 Days — 11.44; 11.58; 11.54; 11.61 g/dL
N/A N=21 Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption
Disorder of Vitamin B12
Primary: Change in Holo-transcobalamin — 124 pmol/L
Phase 3 N=2,628 CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
Pneumonia
Primary: Risk of Treatment Failure. — 267; 253 participants